Ethic Inc. Boosts Stock Holdings in Pfizer Inc. $PFE

Key Points

• Ethic Inc. increased its stake in Pfizer Inc. by 18.8% in Q2, now owning 764,329 shares valued at approximately $18.5 million.
• Pfizer recently reported earnings of $0.78 per share, exceeding analysts' expectations, with revenue up 10.3% year-over-year.
• The company declared a quarterly dividend of $0.43, reflecting an annualized yield of 6.9% with a payout ratio of 91.49%.

Ethic Inc. boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 18.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 764,329 shares of the biopharmaceutical company's stock after buying an additional 120,814 shares during the quarter. Ethic Inc.'s holdings in Pfizer were worth $18,489,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Bessemer Group Inc. lifted its holdings in shares of Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after acquiring an additional 13,228 shares during the period. Capital Advisors Inc. OK raised its holdings in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after buying an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp acquired a new stake in Pfizer in the first quarter valued at approximately $8,283,000. Westbourne Investments Inc. acquired a new position in Pfizer in the 1st quarter worth $2,411,000. Finally, Bourne Lent Asset Management Inc. lifted its stake in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock worth $927,000 after acquiring an additional 18,200 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock opened at $24.81 on Wednesday. The stock has a market cap of $141.03 billion, a PE ratio of 13.19, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.17. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $24.89 and a 200-day simple moving average of $24.13.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer's dividend payout ratio is currently 91.49%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on PFE shares. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. UBS Group reaffirmed a "neutral" rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Bank of America increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. Finally, Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.